Robert Dickey IV joined Invitae as interim chief financial officer in August 2023. He is a finance executive with over 25 years experience as a CFO as well as other C-level and board positions at both private and publicly traded life sciences and medical device companies. Robert is experienced in all stages of the corporate lifecycle, including start-up and fundraising, the IPO process, high growth and turnarounds as well as interactions with directors, shareholders and the investment community. Earlier in his career, he spent 18 years in investment banking, mostly at Lehman Brothers, with a background divided between M&A and capital markets transactions. As a part-time or interim CFO, Rob has consulted with more than 10 companies in the life sciences space. He currently serves as a member of the Board of Directors at AngioGenex, SFA Therapeutics and GSNO Therapeutics. Rob holds an MBA from The Wharton School, University of Pennsylvania, and an AB from Princeton University. Robert holds an MBA from The Wharton School, University of Pennsylvania, and an AB from Princeton University.

Robert Guigley joined Invitae as chief commercial officer in September 2023. In this role, Robert leads Invitae’s commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of clients and patients. 

Robert is an industry veteran with more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He has a deep understanding of the long-term prospects of genetic information, along with extensive experience working with payors.

Most recently, Robert served as the chief commercial officer at Ambry Genetics where he was responsible for executing their commercial strategy and overseeing commercial sales, business development, client services, managing genetic specialists and expanding market access. He began his career in pharmaceutical sales at AstraZeneca, giving him a strong foundation in selling to physicians. He then migrated into diagnostics, leading sales and market access at Quest Diagnostics and Counsyl. 

Robert earned his MBA at Boston University Questrom School of Business and his BS at the University of Pittsburgh, where he focused on economics, math and philosophy.

Dr. Nussbaum leads Invitae’s medical team, which is driving forward the science and practice of medical genetics and improving clinical understanding of how to use genetics to improve patient care. Prior to joining Invitae, he was chief of the Division of Genomic Medicine at UCSF Health where he also held leadership roles in the Cancer Genetics and Prevention Program, and the Program in Cardiovascular Genetics, as well as serving as a member of the UCSF Institute for Human Genetics. Earlier, Dr. Nussbaum was chief of the Genetic Disease Research Branch of the National Human Genome Research Institute, one of the National Institutes of Health. He is a member of the National Academy of Medicine and a fellow at the American Academy of Arts and Sciences. Dr. Nussbaum is a board-certified internist and medical geneticist who holds a B.S. in Applied Mathematics from Harvard College and an M.D. from Harvard Medical School in the Harvard-MIT joint program in Health Sciences and Technology. He completed his residency in internal medicine at Barnes-Jewish Hospital and a fellowship in medical genetics at the Baylor College of Medicine.